NSIS-B.CO Novonesis (Novozymes A/S) B | DK0060336014
Financials
Trends
Details
| Breakdown | 31.12.2027 | 31.12.2026 | Change % |
|---|---|---|---|
| Total Revenue | 35.662.406.150 | 33.192.719.540 | 7.44% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| Operating Expense | -- | -- | -- |
| Selling General and Administrative | -- | -- | -- |
| Research & Development | -- | -- | -- |
| Operating Income | -- | -- | -- |
| Pretax Income | -- | -- | -- |
| Net Income Common Stockholders | -- | -- | -- |
| Basic EPS | 17,66 | 16,05 | 10.05% |
| Diluted EPS | -- | -- | -- |
| Analyst Count | 13 | 13 | 0.00% |
| EBIT | -- | -- | -- |
| EBITDA | -- | -- | -- |